Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO

Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO

Introduction Malignant peritoneal mesothelioma (MPM) is a rare, aggressive tumour arising primarily from the peritoneum. The only potentially curative treatment is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, the majority of patients are not eligible t...

Full description

Saved in:
Bibliographic Details
Main Authors: Job P van Kooten, Jacobus W A Burger, Cornelis Verhoef, Joachim G J V Aerts, Eva V E Madsen, Alexandra R M Brandt-Kerkhof, Stijn L W Koolen, Ron H J Mathijssen, Michelle V Dietz, Niels A D Guchelaar
Format: Article
Language:English
Published: BMJ Publishing Group 2022-06-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/6/e062907.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/12/6/e062907.full

Similar Items